DEVELOPMENT OF THE PIG AS A SECOND SPECIES MODEL FOR TESTING VACCINES AND ADJUVANTS
Animal Parasitic Diseases
2013 Annual Report
1a.Objectives (from AD-416):
Identify functional genetic variations that modulate the immune responses to swine mucosal pathogens; and determine the genetic profiles of ”good responders” to swine vaccines.
1b.Approach (from AD-416):
Out-bred commercial breeds of swine will be vaccinated with recombinant products from bacterial and viral pathogens by various routes including mucosal exposure with novel and conventional adjuvants and vaccine platforms. Local and systemic responses to vaccination will be evaluated by measuring antigen specific antibody isotype responses in the serum, and eye, lung, and intestinal fluids, and local and whole blood changes in cytokine and chemokine biomarkers by gene expression. This information will be used by both ARS and the COOPERATOR to jointly develop novel adaptive and acquired immune readout systems to evaluate vaccine efficacy as it applies to swine directly and as a second species for testing important new vaccine constructs.
Because of the relocation of the principal collaborating group to a new laboratory, loss of supporting personnel, and limited availability of pigs for this project, no new information can be reported for this period. Meetings with collaborators from the cooperating laboratory have been completed with a plan to use data already produced during the project to submit a grant for additional funding.